Tag: clinical oncology next generation sequencing market analysis

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Clinical Oncology Next Generation Sequencing Market Growth Performance Trended Historically, And What Lies Ahead?

The size of the clinical oncology next generation sequencing market has expanded quickly over the recent years. Its growth is projected to continue from $0.51 billion in 2024 to $0.58 billion in 2025, with a compound annual growth rate (CAGR) of 13.9%. The escalations experienced in the historical period can be linked to the advancements in genomic research, the discovery of cancer biomarkers, technological progress, and regulatory approvals.

The size of the clinical oncology next generation sequencing market is projected to experience swift expansion in the ensuing years. By 2029, it’s estimated to increase to $0.94 billion, with a compound annual growth rate (CAGR) of 12.7%. This predicted growth during the forecast period can be related to the rising occurrence of cancer, precision medicine, immuno-oncology, and liquid biopsies. Key trends during this forecast period encompass comprehensive genomic profiling (cgp), immuno-oncology, tumor variation and diversity, as well as artificial intelligence and machine learning.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Clinical Oncology Next Generation Sequencing Market?

The global increase in cancer cases is projected to spur the expansion of the clinical oncology next-generation sequencing market within the forecast period. For example, the National Cancer Institute, a Government agency based in the United States, recorded approximately 18.1 million cancer survivors in the country as of May 2024. This number is anticipated to climb to 22.5 million by 2032. It’s forecasted that by 2040, the annual count of new cancer cases will reach 29.9 million, while the anticipated cancer-related deaths will escalate to 15.3 million. Consequently, the rising global cancer incidence rate is expected to stimulate the demand and growth of the clinical oncology next-generation sequencing market.

Which Primary Segments of the Clinical Oncology Next Generation Sequencing Market Are Driving Growth and Industry Transformations?

The clinical oncology next generation sequencingmarket covered in this report is segmented –

1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing

2) By Application: Screening, Companion Diagnostics, Other Diagnostics

3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories

Subsegments:

1) By Ion Semiconductor Sequencing: Ion Proton System, Ion PGM System, Ion S5 System, Other Ion Semiconductor Sequencing Technologies

2) By Pyro-Sequencing: 454 Pyrosequencing, Other Pyro-Sequencing Technologies

3) By Synthesis Sequencing: Illumina Sequencing Technology, SOLiD Sequencing Technology, Other Synthesis Sequencing Technologies

4) By Real-Time Sequencing: PacBio RS II System, Sequel System, Other Real-Time Sequencing Technologies

5) By Ligation Sequencing: Helicos Single Molecule Sequencing, Other Ligation Sequencing Technologies

6) By Reversible Dye Termination Sequencing: Illumina HiSeq, Illumina NextSeq, Other Reversible Dye Termination Sequencing Technologies

7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION), Other Nano-Pore Sequencing Technologies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=3344&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Clinical Oncology Next Generation Sequencing Market?# Market?

North America was the largest region in the clinical oncology next-generation sequencing market in 2024. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Most Significant Market Trends in the Clinical Oncology Next Generation Sequencing Market?

Leading businesses in the clinical oncology next-generation sequencing market, such as Roche, are introducing revolutionary new products like the BenchMark ULTRA PLUS system. These innovations not only increase their market profitability but also prove invaluable to clinical labs engaged in cancer diagnostics and research. BenchMark ULTRA PLUS assures precise and efficient diagnostic testing, ultimately leading to enhanced patient care. In June 2022, Switzerland’s pharmaceutical giant, Roche introduced this state-of-the-art platform for tissue staining. This system aids clinicians in determining a patient’s treatment course expediently by providing quick and precise test results.

View the full report here:

https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

What Parameters Are Used to Define the Clinical Oncology Next Generation Sequencing Market?

Next generation sequencing (NGS) is a process used to determine the sequence of nucleotides in a section of DNA and is used in oncology research. NGS is used to identify rare cancer mutations and familial cancer mutation carriers and to provide molecular rationale for appropriate targeted therapy.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3344

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Clinical Oncology Next Generation Sequencing Market Growth Performance Trended Historically, And What Lies Ahead?

The size of the clinical oncology next generation sequencing market has expanded quickly over the recent years. Its growth is projected to continue from $0.51 billion in 2024 to $0.58 billion in 2025, with a compound annual growth rate (CAGR) of 13.9%. The escalations experienced in the historical period can be linked to the advancements in genomic research, the discovery of cancer biomarkers, technological progress, and regulatory approvals.

The size of the clinical oncology next generation sequencing market is projected to experience swift expansion in the ensuing years. By 2029, it’s estimated to increase to $0.94 billion, with a compound annual growth rate (CAGR) of 12.7%. This predicted growth during the forecast period can be related to the rising occurrence of cancer, precision medicine, immuno-oncology, and liquid biopsies. Key trends during this forecast period encompass comprehensive genomic profiling (cgp), immuno-oncology, tumor variation and diversity, as well as artificial intelligence and machine learning.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Clinical Oncology Next Generation Sequencing Market?

The global increase in cancer cases is projected to spur the expansion of the clinical oncology next-generation sequencing market within the forecast period. For example, the National Cancer Institute, a Government agency based in the United States, recorded approximately 18.1 million cancer survivors in the country as of May 2024. This number is anticipated to climb to 22.5 million by 2032. It’s forecasted that by 2040, the annual count of new cancer cases will reach 29.9 million, while the anticipated cancer-related deaths will escalate to 15.3 million. Consequently, the rising global cancer incidence rate is expected to stimulate the demand and growth of the clinical oncology next-generation sequencing market.

Which Primary Segments of the Clinical Oncology Next Generation Sequencing Market Are Driving Growth and Industry Transformations?

The clinical oncology next generation sequencingmarket covered in this report is segmented –

1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing

2) By Application: Screening, Companion Diagnostics, Other Diagnostics

3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories

Subsegments:

1) By Ion Semiconductor Sequencing: Ion Proton System, Ion PGM System, Ion S5 System, Other Ion Semiconductor Sequencing Technologies

2) By Pyro-Sequencing: 454 Pyrosequencing, Other Pyro-Sequencing Technologies

3) By Synthesis Sequencing: Illumina Sequencing Technology, SOLiD Sequencing Technology, Other Synthesis Sequencing Technologies

4) By Real-Time Sequencing: PacBio RS II System, Sequel System, Other Real-Time Sequencing Technologies

5) By Ligation Sequencing: Helicos Single Molecule Sequencing, Other Ligation Sequencing Technologies

6) By Reversible Dye Termination Sequencing: Illumina HiSeq, Illumina NextSeq, Other Reversible Dye Termination Sequencing Technologies

7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION), Other Nano-Pore Sequencing Technologies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=3344&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Clinical Oncology Next Generation Sequencing Market?# Market?

North America was the largest region in the clinical oncology next-generation sequencing market in 2024. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Most Significant Market Trends in the Clinical Oncology Next Generation Sequencing Market?

Leading businesses in the clinical oncology next-generation sequencing market, such as Roche, are introducing revolutionary new products like the BenchMark ULTRA PLUS system. These innovations not only increase their market profitability but also prove invaluable to clinical labs engaged in cancer diagnostics and research. BenchMark ULTRA PLUS assures precise and efficient diagnostic testing, ultimately leading to enhanced patient care. In June 2022, Switzerland’s pharmaceutical giant, Roche introduced this state-of-the-art platform for tissue staining. This system aids clinicians in determining a patient’s treatment course expediently by providing quick and precise test results.

View the full report here:

https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

What Parameters Are Used to Define the Clinical Oncology Next Generation Sequencing Market?

Next generation sequencing (NGS) is a process used to determine the sequence of nucleotides in a section of DNA and is used in oncology research. NGS is used to identify rare cancer mutations and familial cancer mutation carriers and to provide molecular rationale for appropriate targeted therapy.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3344

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Clinical Oncology Next Generation Sequencing Market Expected to Grow Between 2025 And 2029?

Recent years have seen the rapid expansion of the clinical oncology next generation sequencing market. Projected growth rates indicate an increase from $0.51 billion in 2024 to $0.58 billion in 2025, marking a compound annual growth rate (CAGR) of 14.8%. This impressive growth throughout the historical period can be traced back to advancements in genomic research, the discovery of cancer biomarkers, technological progression, and regulatory approvals.

What Growth Rate Is Anticipated for the Clinical Oncology Next Generation Sequencing Market in the Coming Years?

In the forthcoming years, the market size of next generation sequencing in clinical oncology is projected to surge swiftly. The estimation predicts a rise to $0.95 billion by 2029, reflecting a compound annual growth rate (CAGR) of 12.9%. Factors contributing to this trend in the forecast period are escalating cases of cancer, accuracy in medicine, immuno-oncology, and liquid biopsies. The predominant trends that are expected to be observed in the forecast period include comprehensive genomic profiling (cgp), developments in immuno-oncology, evolution and heterogeneity of tumors, and the use of artificial intelligence and machine learning.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp

Who Are the Leading Companies in the Clinical Oncology Next Generation Sequencing Market?

Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.

What Are the Key Drivers of the Clinical Oncology Next Generation Sequencing Market?

The increasing prevalence of cancer worldwide is projected to drive the expansion of the clinical oncology next-generation sequencing market in the coming years. The National Cancer Institute, a government agency in the US, reported approximately 18.1 million cancer survivors in the country as of May 2024. This number is expected to climb to 22.5 million by the year 2032. Further estimates suggest that by 2040, the annual tally of novel cancer cases would touch 29.9 million, and there would be an estimated 15.3 million cancer-related deaths. Hence, the global surge in cancer occurrences is poised to stimulate the need for and augment the growth of the clinical oncology next-generation sequencing market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3344&type=smp

What Are the Key Market Segments in the Clinical Oncology Next Generation Sequencing Industry?

The clinical oncology next generation sequencing market covered in this report is segmented –

1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing

2) By Application: Screening, Companion Diagnostics, Other Diagnostics

3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories

Subsegments:

1) By Ion Semiconductor Sequencing: Ion Proton System, Ion PGM System, Ion S5 System, Other Ion Semiconductor Sequencing Technologies

2) By Pyro-Sequencing: 454 Pyrosequencing, Other Pyro-Sequencing Technologies

3) By Synthesis Sequencing: Illumina Sequencing Technology, SOLiD Sequencing Technology, Other Synthesis Sequencing Technologies

4) By Real-Time Sequencing: PacBio RS II System, Sequel System, Other Real-Time Sequencing Technologies

5) By Ligation Sequencing: Helicos Single Molecule Sequencing, Other Ligation Sequencing Technologies

6) By Reversible Dye Termination Sequencing: Illumina HiSeq, Illumina NextSeq, Other Reversible Dye Termination Sequencing Technologies

7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION), Other Nano-Pore Sequencing Technologies

What Are the Latest Trends in the Clinical Oncology Next Generation Sequencing Market?

Leading firms in the clinical oncology next-generation sequencing sector are introducing innovative products like the BenchMark ULTRA PLUS system to boost their market earnings. Especially useful in cancer diagnostics and research, the BenchMark ULTRA PLUS System is a substantial resource for clinical labs as it bolsters the precision and effectiveness of diagnostic examinations, thus enhancing patient care. In June 2022, for example, Roche, a pharmaceutical organization based in Switzerland, unveiled its most advanced tissue staining platform, the BenchMark ULTRA PLUS system. This system provides quick and accurate test results, aiding healthcare professionals in making prompt therapy decisions for their patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

What Are the Key Regional Markets in the Clinical Oncology Next Generation Sequencing Industry?

North America was the largest region in the clinical oncology next-generation sequencing market in 2023. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3344

This Report Delivers Insight On:

1. How big is the clinical oncology next generation sequencing market, and how is it changing globally?

2. Who are the major companies in the clinical oncology next generation sequencing market, and how are they performing?

3. What are the key opportunities and risks in the clinical oncology next generation sequencing market right now?

4. Which products or customer segments are growing the most in the clinical oncology next generation sequencing market?

5. What factors are helping or slowing down the growth of the clinical oncology next generation sequencing market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Clinical Oncology Next Generation Sequencing Market Expected to Grow Between 2025 And 2029?

Recent years have seen the rapid expansion of the clinical oncology next generation sequencing market. Projected growth rates indicate an increase from $0.51 billion in 2024 to $0.58 billion in 2025, marking a compound annual growth rate (CAGR) of 14.8%. This impressive growth throughout the historical period can be traced back to advancements in genomic research, the discovery of cancer biomarkers, technological progression, and regulatory approvals.

What Growth Rate Is Anticipated for the Clinical Oncology Next Generation Sequencing Market in the Coming Years?

In the forthcoming years, the market size of next generation sequencing in clinical oncology is projected to surge swiftly. The estimation predicts a rise to $0.95 billion by 2029, reflecting a compound annual growth rate (CAGR) of 12.9%. Factors contributing to this trend in the forecast period are escalating cases of cancer, accuracy in medicine, immuno-oncology, and liquid biopsies. The predominant trends that are expected to be observed in the forecast period include comprehensive genomic profiling (cgp), developments in immuno-oncology, evolution and heterogeneity of tumors, and the use of artificial intelligence and machine learning.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp

Who Are the Leading Companies in the Clinical Oncology Next Generation Sequencing Market?

Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.

What Are the Key Drivers of the Clinical Oncology Next Generation Sequencing Market?

The increasing prevalence of cancer worldwide is projected to drive the expansion of the clinical oncology next-generation sequencing market in the coming years. The National Cancer Institute, a government agency in the US, reported approximately 18.1 million cancer survivors in the country as of May 2024. This number is expected to climb to 22.5 million by the year 2032. Further estimates suggest that by 2040, the annual tally of novel cancer cases would touch 29.9 million, and there would be an estimated 15.3 million cancer-related deaths. Hence, the global surge in cancer occurrences is poised to stimulate the need for and augment the growth of the clinical oncology next-generation sequencing market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3344&type=smp

What Are the Key Market Segments in the Clinical Oncology Next Generation Sequencing Industry?

The clinical oncology next generation sequencing market covered in this report is segmented –

1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing

2) By Application: Screening, Companion Diagnostics, Other Diagnostics

3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories

Subsegments:

1) By Ion Semiconductor Sequencing: Ion Proton System, Ion PGM System, Ion S5 System, Other Ion Semiconductor Sequencing Technologies

2) By Pyro-Sequencing: 454 Pyrosequencing, Other Pyro-Sequencing Technologies

3) By Synthesis Sequencing: Illumina Sequencing Technology, SOLiD Sequencing Technology, Other Synthesis Sequencing Technologies

4) By Real-Time Sequencing: PacBio RS II System, Sequel System, Other Real-Time Sequencing Technologies

5) By Ligation Sequencing: Helicos Single Molecule Sequencing, Other Ligation Sequencing Technologies

6) By Reversible Dye Termination Sequencing: Illumina HiSeq, Illumina NextSeq, Other Reversible Dye Termination Sequencing Technologies

7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION), Other Nano-Pore Sequencing Technologies

What Are the Latest Trends in the Clinical Oncology Next Generation Sequencing Market?

Leading firms in the clinical oncology next-generation sequencing sector are introducing innovative products like the BenchMark ULTRA PLUS system to boost their market earnings. Especially useful in cancer diagnostics and research, the BenchMark ULTRA PLUS System is a substantial resource for clinical labs as it bolsters the precision and effectiveness of diagnostic examinations, thus enhancing patient care. In June 2022, for example, Roche, a pharmaceutical organization based in Switzerland, unveiled its most advanced tissue staining platform, the BenchMark ULTRA PLUS system. This system provides quick and accurate test results, aiding healthcare professionals in making prompt therapy decisions for their patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

What Are the Key Regional Markets in the Clinical Oncology Next Generation Sequencing Industry?

North America was the largest region in the clinical oncology next-generation sequencing market in 2023. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3344

This Report Delivers Insight On:

1. How big is the clinical oncology next generation sequencing market, and how is it changing globally?

2. Who are the major companies in the clinical oncology next generation sequencing market, and how are they performing?

3. What are the key opportunities and risks in the clinical oncology next generation sequencing market right now?

4. Which products or customer segments are growing the most in the clinical oncology next generation sequencing market?

5. What factors are helping or slowing down the growth of the clinical oncology next generation sequencing market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the clinical oncology next generation sequencing industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Current and Projected Market Size of the Clinical Oncology Next Generation Sequencing Market Through 2034?

There has been significant growth in the clinical oncology next generation sequencing market in the past few years. This market is projected to increase from $0.51 billion in 2024 to $0.58 billion in 2025, reflecting a compound annual growth rate (CAGR) of 14.8%. The expansion during the historic period can be linked to advances in genomic research, the detection of cancer biomarkers, technological progress, and regulatory approvals.

The market size of clinical oncology next generation sequencing is predicted to experience rapid expansion in the upcoming years, expected to reach $0.95 billion by 2029, with a compound annual growth rate (CAGR) of 12.9%. The expected growth during the forecast period is due to an increase in cancer incidences, the rise of precision medicine, developments in immuno-oncology, and the use of liquid biopsies. The major trend drivers during the forecast period are expected to be comprehensive genomic profiling (cgp), further advancements in immuno-oncology, an understanding of tumor evolution and heterogeneity, as well as the integration of AI and machine learning.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp

What Are the Core Market Drivers Propelling Growth in the Clinical Oncology Next Generation Sequencing Industry?

The escalation in global cancer cases is anticipated to fuel the expansion of the clinical oncology next-generation sequencing market in the approaching years. For instance, data from the National Cancer Institute, a US government agency, revealed approximately 18.1 million cancer survivors in May 2024 in the United States. Such figures are estimated to climb to 22.5 million by 2032. It’s predicted that by 2040, the annual number of new cancer cases will hit 29.9 million, while cancer-related deaths are projected to rise to 15.3 million. Consequently, the increasing global cancer incidence rate is expected to stimulate the demand and growth of the clinical oncology next-generation sequencing market.

How Is the Clinical Oncology Next Generation Sequencing Market Segmented?

The clinical oncology next generation sequencing market covered in this report is segmented –

1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing

2) By Application: Screening, Companion Diagnostics, Other Diagnostics

3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories

Subsegments:

1) By Ion Semiconductor Sequencing: Ion Proton System, Ion PGM System, Ion S5 System, Other Ion Semiconductor Sequencing Technologies

2) By Pyro-Sequencing: 454 Pyrosequencing, Other Pyro-Sequencing Technologies

3) By Synthesis Sequencing: Illumina Sequencing Technology, SOLiD Sequencing Technology, Other Synthesis Sequencing Technologies

4) By Real-Time Sequencing: PacBio RS II System, Sequel System, Other Real-Time Sequencing Technologies

5) By Ligation Sequencing: Helicos Single Molecule Sequencing, Other Ligation Sequencing Technologies

6) By Reversible Dye Termination Sequencing: Illumina HiSeq, Illumina NextSeq, Other Reversible Dye Termination Sequencing Technologies

7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION), Other Nano-Pore Sequencing Technologies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=3344&type=smp

Which Regions Are Driving the Next Phase of the Clinical Oncology Next Generation Sequencing Market Growth?

North America was the largest region in the clinical oncology next-generation sequencing market in 2023. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Key Trends Are Shaping the Future of the Clinical Oncology Next Generation Sequencing Market?

Leading enterprises in the clinical oncology next-generation sequencing market are introducing innovative products like the BenchMark ULTRA PLUS system to boost their market profitability. Especially useful for clinical labs engaged in cancer diagnostics and research, the BenchMark ULTRA PLUS System enhances the precision and effectiveness of diagnostic procedures, thereby promoting better patient care. Roche, a pharmaceutical firm based in Switzerland, for example, launched the BenchMark ULTRA PLUS system, their most advanced tissue staining platform in June 2022. This system facilitates quick and precise test results, enabling clinicians to decide on a patient’s treatment path efficiently.

View the full report here:

https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

How Is the Clinical Oncology Next Generation Sequencing Market Defined and What Are Its Core Parameters?

Next generation sequencing (NGS) is a process used to determine the sequence of nucleotides in a section of DNA and is used in oncology research. NGS is used to identify rare cancer mutations and familial cancer mutation carriers and to provide molecular rationale for appropriate targeted therapy.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3344

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Industry-Specific Factors Are Fueling the Growth of theClinical Oncology Next Generation Sequencing Market?

The rising incidence of cancer globally is anticipated to contribute to the growth of the clinical oncology next-generation sequencing market. For instance, the National Cancer Institute (NCI) reported that there were 18.1 million cancer survivors in the U.S. in May 2024, a number expected to increase to 22.5 million by 2032. By 2040, it is projected that new cancer cases will reach 29.9 million annually, with cancer-related deaths rising to 15.3 million. As a result, the increasing cancer incidence is expected to drive demand for clinical oncology next-generation sequencing technologies.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp

#What Growth Opportunities Will Drive the Clinical Oncology Next Generation Sequencing Market’s CAGR Through 2034?

The clinical oncology next generation sequencing market has expanded rapidly in recent years. It is projected to grow from $0.51 billion in 2024 to $0.58 billion in 2025, at a CAGR of 14.8%. This growth has been driven by progress in genomic research, discovery of cancer biomarkers, advancements in sequencing technologies, and regulatory clearances.

The clinical oncology next-generation sequencing market is set for rapid growth, reaching $0.95 billion by 2029 at a CAGR of 12.9%. This growth is driven by increasing cancer incidence and advancements in precision medicine. Trends include comprehensive genomic profiling (CGP), tumor evolution research, and AI-powered tools.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3344

What Key Market Trends and Innovations Are Shaping the Future of theClinical Oncology Next Generation Sequencing Industry?

In the clinical oncology next-generation sequencing market, firms are launching advanced diagnostic tools like the BenchMark ULTRA PLUS system. Released in June 2022 by Roche, this system enhances accuracy and speed in tissue staining for cancer diagnostics, supporting timely and informed treatment decisions in clinical labs.

Which Companies Are Leading the Charge in Expanding theClinical Oncology Next Generation Sequencing Market Growth?

Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

How is the Global Clinical Oncology Next Generation Sequencing Market Segemented?

The clinical oncology next generation sequencing market covered in this report is segmented –

1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing

2) By Application: Screening, Companion Diagnostics, Other Diagnostics

3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories

Subsegments:

1) By Ion Semiconductor Sequencing: Ion Proton System, Ion PGM System, Ion S5 System, Other Ion Semiconductor Sequencing Technologies

2) By Pyro-Sequencing: 454 Pyrosequencing, Other Pyro-Sequencing Technologies

3) By Synthesis Sequencing: Illumina Sequencing Technology, SOLiD Sequencing Technology, Other Synthesis Sequencing Technologies

4) By Real-Time Sequencing: PacBio RS II System, Sequel System, Other Real-Time Sequencing Technologies

5) By Ligation Sequencing: Helicos Single Molecule Sequencing, Other Ligation Sequencing Technologies

6) By Reversible Dye Termination Sequencing: Illumina HiSeq, Illumina NextSeq, Other Reversible Dye Termination Sequencing Technologies

7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION), Other Nano-Pore Sequencing Technologies

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=3344&type=smp

Which Geographics are Influencing the Growth of the Clinical Oncology Next Generation Sequencing Market?

North America was the largest region in the clinical oncology next-generation sequencing market in 2023. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Global Clinical Oncology Next Generation Sequencing Market 2025, By The Business Research Company:

Oncology Molecular Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-molecular-diagnostics-global-market-report

RNA Analysis/ Transcriptomics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/rna-analysis-transcriptomics-global-market-report

Human Microbiome Therapeutics Global Market Opportunities And Strategies To 2030: COVID-19 Growth and Change

https://www.thebusinessresearchcompany.com/report/human-microbiome-therapeutics-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the clinical oncology next generation sequencing market grown in recent years?

The market size of clinical oncology next-generation sequencing has seen swift expansion in the past few years. The market will see an increase from $0.51 billion in 2024 to $0.58 billion in 2025, showing a compound annual growth rate (CAGR) of 14.8%. The growth observed in the historic period is a consequence of advancements in genomic research, discovery of cancer biomarkers, technological progress, and regulatory approvals.

How is the clinical oncology next generation sequencing market size expected to evolve during the forecast period?

In the coming years, a significant upsurge is anticipated for the clinical oncology next generation sequencing market, with expectations to attain $0.95 billion by 2029, expanding at a compound annual growth rate (CAGR) of 12.9%. This escalation over the predicted period can be linked to the rising incidence of cancer, precise medical methodologies, immuno-oncology, and liquid biopsies. Noteworthy tendencies during the projected period comprise comprehensive genomic profiling (cgp), advancements in immuno-oncology, the varying nature and diversity of tumors, along with the integration of AI and machine learning.

Get your clinical oncology next generation sequencing market report here!

https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp

Which key drivers are propelling the clinical oncology next generation sequencing market’s growth?

The increase in global cancer incidence is expected to drive the expansion of the clinical oncology next-generation sequencing market during the projected timeline. For example, the National Cancer Institute, a US government agency, reported in May 2024 that approximately 18.1 million cancer survivors were residing in the United States. This figure is expected to grow to 22.5 million by 2032. It is predicted that by 2040, the annual number of new cancer cases will hit 29.9 million, and cancer-related fatalities are forecasted to rise to 15.3 million. As a result, the surge in global cancer occurrence rates is foreseen to stimulate demand and foster the development of the clinical oncology next-generation sequencing market.

What are the market segments in the clinical oncology next generation sequencing industry?

The clinical oncology next generation sequencing market covered in this report is segmented –

1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing

2) By Application: Screening, Companion Diagnostics, Other Diagnostics

3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories

Subsegments:

1) By Ion Semiconductor Sequencing: Ion Proton System, Ion PGM System, Ion S5 System, Other Ion Semiconductor Sequencing Technologies

2) By Pyro-Sequencing: 454 Pyrosequencing, Other Pyro-Sequencing Technologies

3) By Synthesis Sequencing: Illumina Sequencing Technology, SOLiD Sequencing Technology, Other Synthesis Sequencing Technologies

4) By Real-Time Sequencing: PacBio RS II System, Sequel System, Other Real-Time Sequencing Technologies

5) By Ligation Sequencing: Helicos Single Molecule Sequencing, Other Ligation Sequencing Technologies

6) By Reversible Dye Termination Sequencing: Illumina HiSeq, Illumina NextSeq, Other Reversible Dye Termination Sequencing Technologies

7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION), Other Nano-Pore Sequencing Technologies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp

Which leading companies are shaping the growth of the clinical oncology next generation sequencing market?

Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.

What key trends are currently impacting the clinical oncology next generation sequencing market’s development?

Leading corporations in the clinical oncology next-generation sequencing market are introducing innovative products such as the BenchMark ULTRA PLUS system to enhance their market profitability. The BenchMark ULTRA PLUS System provides immense value to clinical labs, especially those focused on cancer research and diagnosis, since it improves the precision and effectiveness of diagnostic tests, leading to superior patient care. As an example, the BenchMark ULTRA PLUS system, the most advanced platform for tissue staining, was launched in June 2022 by Roche, a Swiss-based pharmaceutical firm. The system expedites accurate test results, aiding clinicians in making timely decisions regarding a patient’s treatment course.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3344

Which geographic areas are influencing the growth of the clinical oncology next generation sequencing market?

North America was the largest region in the clinical oncology next-generation sequencing market in 2023. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Oncology Molecular Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-molecular-diagnostics-global-market-report

RNA Analysis/ Transcriptomics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/rna-analysis-transcriptomics-global-market-report

Human Microbiome Therapeutics Global Market Opportunities And Strategies To 2030: COVID-19 Growth and Change

https://www.thebusinessresearchcompany.com/report/human-microbiome-therapeutics-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Clinical Oncology Next Generation Sequencing Market Grow Over the Forecast Period Based on Its Expected CAGR?

The market size of clinical oncology next-generation sequencing has seen swift expansion in the past few years. The market will see an increase from $0.51 billion in 2024 to $0.58 billion in 2025, showing a compound annual growth rate (CAGR) of 14.8%. The growth observed in the historic period is a consequence of advancements in genomic research, discovery of cancer biomarkers, technological progress, and regulatory approvals.

In the coming years, a significant upsurge is anticipated for the clinical oncology next generation sequencing market, with expectations to attain $0.95 billion by 2029, expanding at a compound annual growth rate (CAGR) of 12.9%. This escalation over the predicted period can be linked to the rising incidence of cancer, precise medical methodologies, immuno-oncology, and liquid biopsies. Noteworthy tendencies during the projected period comprise comprehensive genomic profiling (cgp), advancements in immuno-oncology, the varying nature and diversity of tumors, along with the integration of AI and machine learning.

What Are the Primary Drivers Supporting the Growth of the Clinical Oncology Next Generation Sequencing Market?

The increase in global cancer incidence is expected to drive the expansion of the clinical oncology next-generation sequencing market during the projected timeline. For example, the National Cancer Institute, a US government agency, reported in May 2024 that approximately 18.1 million cancer survivors were residing in the United States. This figure is expected to grow to 22.5 million by 2032. It is predicted that by 2040, the annual number of new cancer cases will hit 29.9 million, and cancer-related fatalities are forecasted to rise to 15.3 million. As a result, the surge in global cancer occurrence rates is foreseen to stimulate demand and foster the development of the clinical oncology next-generation sequencing market.

Explore Comprehensive Insights Into The Global Clinical Oncology Next Generation Sequencing Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp

Who Are the Dominant Players Expanding Their Reach in the Clinical Oncology Next Generation Sequencing Market?

Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.

What Are the Top Trends Shaping the Evolution of the Clinical Oncology Next Generation Sequencing Market?

Leading corporations in the clinical oncology next-generation sequencing market are introducing innovative products such as the BenchMark ULTRA PLUS system to enhance their market profitability. The BenchMark ULTRA PLUS System provides immense value to clinical labs, especially those focused on cancer research and diagnosis, since it improves the precision and effectiveness of diagnostic tests, leading to superior patient care. As an example, the BenchMark ULTRA PLUS system, the most advanced platform for tissue staining, was launched in June 2022 by Roche, a Swiss-based pharmaceutical firm. The system expedites accurate test results, aiding clinicians in making timely decisions regarding a patient’s treatment course.

Secure Your Global Clinical Oncology Next Generation Sequencing Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

What Are the Core Segments of the Clinical Oncology Next Generation Sequencing Market, and How Do They Contribute to Growth?

The clinical oncology next generation sequencing market covered in this report is segmented –

1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing

2) By Application: Screening, Companion Diagnostics, Other Diagnostics

3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories

Subsegments:

1) By Ion Semiconductor Sequencing: Ion Proton System, Ion PGM System, Ion S5 System, Other Ion Semiconductor Sequencing Technologies

2) By Pyro-Sequencing: 454 Pyrosequencing, Other Pyro-Sequencing Technologies

3) By Synthesis Sequencing: Illumina Sequencing Technology, SOLiD Sequencing Technology, Other Synthesis Sequencing Technologies

4) By Real-Time Sequencing: PacBio RS II System, Sequel System, Other Real-Time Sequencing Technologies

5) By Ligation Sequencing: Helicos Single Molecule Sequencing, Other Ligation Sequencing Technologies

6) By Reversible Dye Termination Sequencing: Illumina HiSeq, Illumina NextSeq, Other Reversible Dye Termination Sequencing Technologies

7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION), Other Nano-Pore Sequencing Technologies

Which Regions Are Setting the Pace for Clinical Oncology Next Generation Sequencing Market Growth?

North America was the largest region in the clinical oncology next-generation sequencing market in 2023. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

How Is the Clinical Oncology Next Generation Sequencing Market Defined Across Different Regions?

Next generation sequencing (NGS) is a process used to determine the sequence of nucleotides in a section of DNA and is used in oncology research. NGS is used to identify rare cancer mutations and familial cancer mutation carriers and to provide molecular rationale for appropriate targeted therapy.

Browse Through More Similar Reports By The Business Research Company:

Oncology Molecular Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-molecular-diagnostics-global-market-report

RNA Analysis/ Transcriptomics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/rna-analysis-transcriptomics-global-market-report

Human Microbiome Therapeutics Global Market Opportunities And Strategies To 2030: COVID-19 Growth and Change

https://www.thebusinessresearchcompany.com/report/human-microbiome-therapeutics-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: